Could an alcoholism drug plus copper fight breast cancer?
NCT ID NCT03323346
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested whether disulfiram (Antabuse), a drug used for alcoholism, combined with copper supplements could help people with metastatic breast cancer who had run out of standard options. Only 9 patients took part, and researchers measured tumor response and survival. The study is complete, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
disulfiram (Antabuse) plus copper supplement
What this could lead to
If it works, this could offer a new treatment option for metastatic breast cancer when standard therapies have failed.
What could go wrong
This is a very small Phase 2 trial with only 9 participants, so results may not apply broadly. The drug combination may not shrink tumors or improve survival, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Olomouc
Olomouc, 77900, Czechia